PEP Drugs List in India 2025 — Complete Guide

What is PEP and Why Does the Drug Choice Matter?

PEP (Post-Exposure Prophylaxis) is an emergency HIV prevention treatment consisting of antiretroviral medicines taken after a potential HIV exposure. The specific drug combination used in your regimen — matters significantly: different combinations vary in side effect profiles, dosing frequency, drug interactions, and tolerability. Choosing the wrong regimen for a patient's specific circumstances can result in poor adherence, which directly reduces effectiveness.

PEP must be started within 72 hours of exposure (ideally within 2 hours) and taken consistently for 28 to 30 days. When started early and taken correctly, modern PEP regimens are up to 98% effective at preventing HIV infection. This effectiveness figure is conditional — it requires early initiation and consistent adherence throughout the full course.

The Evolution of PEP Regimens: 1996 to 2025

1996-2005: The Zidovudine (AZT) Era

PEP was first formally recommended in 1996, following studies in healthcare workers who had experienced needle-stick injuries. The initial regimen was a single drug: zidovudine (ZDV/AZT), taken multiple times daily for 28 days. While it demonstrated a protective effect, zidovudine-based monotherapy had significant limitations: frequent dosing (2–4 times daily), substantial side effects (nausea, fatigue, headache, anaemia), and limited efficacy compared to later combinations.

By the early 2000s, guidelines moved to two-drug combinations, adding lamivudine (3TC) to zidovudine — a more effective approach, though side effects remained a significant barrier to full adherence.

2005–2015: Three-Drug Regimens Become Standard

As combination antiretroviral therapy proved dramatically more effective for HIV treatment, three-drug regimens became the standard of care for PEP as well. Commonly used combinations included: AZT + 3TC + lopinavir/ritonavir, and later tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir or efavirenz-based combinations. These offered better viral suppression but still involved twice-daily dosing, and significant side effects from the boosted protease inhibitor component.

2015–2020: Integrase Inhibitors Transform PEP

The introduction of integrase strand transfer inhibitors (INSTIs) — particularly raltegravir and then dolutegravir — significantly improved PEP tolerability. These drugs interfere with HIV's ability to insert its genetic material into the host cell's DNA, preventing viral integration. They cause fewer side effects than protease inhibitors, have minimal drug interactions compared to older agents, and are well tolerated. The combination of TDF/FTC with raltegravir became widely recommended.

2020–2025: The Dolutegravir and Bictegravir Standard

The current (2025) preferred PEP regimens in India and globally are built around Dolutegravir (DTG) or Bictegravir (BIC) combined with either Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC) or the newer Tenofovir Alafenamide / Emtricitabine (TAF/FTC).

Key advantages of modern DTG/BIC-based regimens:

• Once-daily dosing (some regimens available as a single tablet)
• Excellent tolerability — most patients complete the full 28-day course with minimal disruption
• High genetic barrier to resistance — DTG and BIC are extremely difficult for HIV to develop resistance to
• Minimal drug interactions compared to protease inhibitor-based regimens
• Available as generic formulations in India at substantially lower cost than branded versions

PEP Drug Regimens Available in India (2025)

The following are the primary drug classes used in PEP regimens available in India. This information is provided for educational purposes only — drug selection must be made by a qualified specialist based on individual patient factors.

Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)

The backbone of most modern PEP regimens. TDF/FTC is a fixed-dose combination taken once daily. Tenofovir inhibits HIV reverse transcriptase; emtricitabine does the same through a complementary mechanism. Generic TDF/FTC is widely available in India at affordable prices. Side effects are generally mild but can include nausea (especially in the first week) and, with long-term use, kidney function effects (monitored with periodic blood tests).

Tenofovir Alafenamide + Emtricitabine (TAF/FTC)

A newer formulation of tenofovir (TAF) that delivers the active drug more efficiently at lower doses. TAF/FTC has a better kidney and bone safety profile than TDF/FTC and is preferred for patients with pre-existing kidney concerns. Currently more expensive than TDF/FTC generics in India.

Dolutegravir (DTG)

The preferred third agent in India's national PEP guidelines. DTG is an integrase inhibitor with once-daily dosing, excellent tolerability, and a high barrier to resistance. Generic dolutegravir is available in India. It should be avoided in the first trimester of pregnancy (due to historical neural tube defect concerns, though evidence is nuanced — specialist consultation essential).

Bictegravir (BIC)

Available only as part of a fixed-dose single-tablet regimen (with TAF and emtricitabine). Bictegravir has an excellent tolerability profile and the highest genetic barrier to resistance of any INSTI. Currently more expensive than DTG-based generics in India.

Raltegravir (RAL)

An earlier integrase inhibitor, used in some PEP regimens — particularly when DTG or BIC is contraindicated. Requires twice-daily dosing, which makes adherence slightly more challenging. Still a valid option in specific circumstances.

What Determines Your PEP Treatment Cost

✎ Rewritten — no price list, by design

PEP cost varies meaningfully from patient to patient, because the right regimen for you depends on your specific exposure, health history, and tolerance — not a fixed formula. Rather than publish a generic price list that may not reflect your actual situation (or may already be out of date by the time you read it), here's what genuinely drives the cost, so you know exactly what you're paying for before you commit to anything.

What else affects your final cost:

How is the Right PEP Regimen Selected?

Regimen selection is not one-size-fits-all. Dr. Monga considers several factors when prescribing PEP:

• Nature of exposure: Specific exposure types carry different baseline transmission risks
• HIV status of source (if known): Whether the source person is known positive, unknown, or on treatment
• Patient's other medications: Some drugs interact with PEP components
• Kidney function: Important for tenofovir-based regimens
• Pregnancy or possibility of pregnancy: Affects DTG choice in early pregnancy
• Patient's ability to adhere to dosing schedule: Once-daily vs. twice-daily
• Cost constraints: Generic options discussed transparently

This personalised assessment is why consulting a specialist rather than attempting to self-prescribe PEP is strongly recommended — even if a patient can obtain the medicines. Incorrect regimen selection or suboptimal adherence can result in preventable treatment failure.

Starting PEP — What to Expect

If you are within 72 hours of a potential HIV exposure and decide to start PEP:

• Act immediately — every hour of delay reduces efficacy. Start as soon as possible after the exposure, ideally within 2 hours.
• Baseline HIV test — before starting PEP, a baseline HIV test confirms your current status. This is critical for interpreting follow-up tests.
• Take every dose — missing doses significantly reduces the chance of PEP being effective. Set reminders. If you miss a dose, take it as soon as you remember and continue as normal.
• Complete the full 28 days — stopping early, even if you feel fine, is not recommended.
• Follow-up testing — HIV tests at 4-6 weeks and 3 months after exposure confirm whether PEP was successful.